

AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-305-671-0200.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Vigabatrin Products

Drug Requested: (select drug below)

<input type="checkbox"/> Sabril® (vigabatrin) tablets	<input type="checkbox"/> Sabril® (vigabatrin) packets
<input type="checkbox"/> vigabatrin packets	<input type="checkbox"/> vigabatrin tablets
<input type="checkbox"/> Vigadrone® (vigabatrin) packets	<input type="checkbox"/> Vigafyde™ (vigabatrin) solution
<input type="checkbox"/> Vigpoder® (vigabatrin) packets	

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Weight (must be measured within the last 30 days): _____ kg Date weight obtained: _____

- Will the member be discontinuing a previously prescribed vigabatrin product if approved for requested medication?
 Yes **OR** No

- If yes, please list the medication that will be discontinued and the medication that will be initiated upon approval along with the corresponding effective date.

Medication to be discontinued: _____ Effective date: _____

Medication to be initiated: _____ Effective date: _____

(Continued on next page)

Recommended Dosage:

Indication	Dose
Infantile spasms	<ul style="list-style-type: none"> • Infants and Children 1 month to 2 years of age: Oral: Powder for oral solution: Initial: 50 mg/kg/day divided twice daily; may titrate upwards by 25 to 50 mg/kg/day increments every 3 days based on response and tolerability; maximum daily dose: 150 mg/kg/day divided twice daily; Note: To taper, decrease dose by 25 to 50 mg/kg/day every 3 to 4 days. • Withdraw therapy in 2 to 4 weeks if a substantial clinical benefit is not observed or discontinue treatment if evidence of treatment failure becomes obvious earlier than 2 to 4 weeks.
Refractory complex partial seizures, adjunctive treatment	<ul style="list-style-type: none"> • Dose dependent upon weight and/or age. • Withdraw therapy if a substantial clinical benefit is not observed within 3 months of treatment initiation; discontinue therapy if evidence of treatment failure becomes obvious earlier than 3 months.

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied. Check box below for the Diagnosis that applies.

Initial Authorization: 6 months

DIAGNOSIS: (Please check one of the applicable diagnoses below)

Infantile Spasms

- Prescribing physician is a neurologist or has consulted with a neurologist
- Member is between the ages of 1 month and 2 years of age with a diagnosis of infantile spasms
- Member must meet **ONE** of the following:
 - Member's baseline vision has been assessed by an ophthalmologist or the member's vision will be assessed within 4 weeks of initiating vigabatrin therapy and at least every 3 months while on therapy. Vision testing is also recommended 3 to 6 months after discontinuation of vigabatrin therapy
 - Member is blind or has been formally exempt from vision assessment in the Vigabatrin REMS Program
- Requested dose does **NOT** exceed FDA approved maximum dose for indication

(Continued on next page)

❑ Refractory Complex Partial Seizures (CPS)

- ❑ Prescribing physician is a neurologist or has consulted with a neurologist
- ❑ Member is 2 years of age or older with refractory complex partial seizures who has responded inadequately to alternative treatments
- ❑ Member has tried and failed at least **THREE (3)** antiepileptic medications for complex partial seizures such as carbamazepine, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, topiramate, valproic acid, divalproex sodium, or zonisamide (**verified by chart notes and/or pharmacy paid claims**)
- ❑ Vigabatrin will be used in combination with at least **ONE (1)** one other antiepileptic medication (**verified by chart notes and/or pharmacy paid claims**)
- ❑ Member must meet **ONE** of the following:
 - ❑ Members baseline vision has been assessed by an ophthalmologist or the member's vision will be assessed within 4 weeks of initiating Sabril therapy and at least every 3 months while on therapy. Vision testing is also recommended 3 to 6 months after discontinuation of Sabril therapy
 - ❑ Member is blind or has been formally exempt from vision assessment in the Vigabatrin REMS Program
- ❑ Requested dose does **NOT** exceed FDA approved maximum dose for indication

Reauthorization: 12 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

❑ For Both Infantile Spasms and Refractory Complex Partial Seizures (CPS)

- ❑ Member continues to meet **ALL** initial criteria listed above for the applicable diagnosis
- ❑ Provider must submit current progress notes documenting efficacy demonstrating that member is stable from baseline or has a positive response to vigabatrin therapy
- ❑ Requested dose does **NOT** exceed FDA approved maximum dose for indication

Medication being provided by Specialty Pharmacy – Proprium Rx

Not all drugs may be covered under every Plan

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****